[1] |
Quigley HA. Glaucoma. Lancet, 2011, 377(9774): 1367-1377.
|
|
DOI: 10.1016/S0140-6736(10)61423-7.
|
[1] |
Quigley HA. Glaucoma. Lancet, 2011, 377(9774): 1367-1377.
|
|
DOI: 10.1016/S0140-6736(10)61423-7.
|
[2] |
Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive
|
[2] |
Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive
|
|
factors for glaucomatous visual field progression in the
|
|
factors for glaucomatous visual field progression in the
|
|
Advanced Glaucoma Intervention Study. Ophthalmology, 2004,
|
11 |
1(9): 1627-1635. DOI: 10.1016/j.ophtha.2004.02.017.
|
|
Advanced Glaucoma Intervention Study. Ophthalmology, 2004,
|
11 |
1(9): 1627-1635. DOI: 10.1016/j.ophtha.2004.02.017.
|
[3] |
Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical
|
[3] |
Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical
|
|
outcomes in the Collaborative Initial Glaucoma Treament
|
|
outcomes in the Collaborative Initial Glaucoma Treament
|
|
Study comparing initial treatment randomized to medications or
|
|
surgery. Ophthalmology, 2001, 108(11): 1943-1953.
|
|
Study comparing initial treatment randomized to medications or
|
[4] |
Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma
|
|
surgery. Ophthalmology, 2001, 108(11): 1943-1953.
|
|
progression and the effect of treatment: the early manifest
|
[4] |
Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma
|
|
glaucoma trial. Arch Ophthalmol, 2003, 121(1): 48-56.
|
|
progression and the effect of treatment: the early manifest
|
[5] |
Krupin T, Liebmann JM, Greenfield DS, et al. A randomized
|
|
glaucoma trial. Arch Ophthalmol, 2003, 121(1): 48-56.
|
|
trial of brimonidine versus timolol in preserving visual function:
|
[5] |
Krupin T, Liebmann JM, Greenfield DS, et al. A randomized
|
|
trial of brimonidine versus timolol in preserving visual function:
|
|
results from the Low-Pressure Glaucoma Treatment Study.
|
|
Am J Ophthalmol, 2011, 151(4): 671-681. DOI: 10.1016/
|
|
results from the Low-Pressure Glaucoma Treatment Study.
|
|
Am J Ophthalmol, 2011, 151(4): 671-681. DOI: 10.1016/
|
|
j.ajo.2010.09.026.
|
|
j.ajo.2010.09.026.
|
[6] |
Fang J, Jiang F, Li J, et al. Rationale for the use of
|
[6] |
Fang J, Jiang F, Li J, et al. Rationale for the use of
|
|
multifunctional drugs as neuroprotective agents for glaucoma.
|
|
Neural Regen Res, 2012, 7(4): 313-318. DOI: 10.3969/
|
|
multifunctional drugs as neuroprotective agents for glaucoma.
|
|
j.issn.1673-5374.2012.04.013.
|
|
Neural Regen Res, 2012, 7(4): 313-318. DOI: 10.3969/
|
|
j.issn.1673-5374.2012.04.013.
|
[7] |
王振军. 单味中药及其有效成分保护青光眼视神经作用机
|
|
制的研究进展. 医药导报, 2011, 30(1): 73-78. DOI: 10.3870/
|
|
yydb.2011.01.024.
|
[7] |
王振军. 单味中药及其有效成分保护青光眼视神经作用机
|
|
制的研究进展. 医药导报, 2011, 30(1): 73-78. DOI: 10.3870/
|
|
yydb.2011.01.024.
|
[8] |
Nickells RW, Semaan SJ, Schlamp CL. Involvement of the Bcl 2
|
[8] |
Nickells RW, Semaan SJ, Schlamp CL. Involvement of the Bcl 2
|
|
gene family in the signaling and control of retinal ganglion
|
|
cell death. Prog Brain Res, 2008, 173: 423-435. DOI: 10.1016/
|
|
gene family in the signaling and control of retinal ganglion
|
|
cell death. Prog Brain Res, 2008, 173: 423-435. DOI: 10.1016/
|
|
S0079-6123(08)01129-1.
|
|
S0079-6123(08)01129-1.
|
[9] |
Levkovitch-Verbin H. Retinal ganglion cell apoptotic pathway
|
[9] |
Levkovitch-Verbin H. Retinal ganglion cell apoptotic pathway
|
|
in glaucoma: initiating and downstream mechanisms. Prog Brain
|
|
Res, 2015, 220: 37-57. DOI: 10.1016/bs.pbr.2015.05.005.
|
|
in glaucoma: initiating and downstream mechanisms. Prog Brain
|
|
Res, 2015, 220: 37-57. DOI: 10.1016/bs.pbr.2015.05.005.
|
[10] |
Almasieh M, Wilson AM, Morquette B, et al. The molecular
|
[10] |
Almasieh M, Wilson AM, Morquette B, et al. The molecular
|
|
basis of retinal ganglion cell death in glaucoma. Prog Retin Eye
|
|
Res, 2012, 31(2): 152-181. DOI: 10.1016/j.preteyeres.2011.11.
|
|
basis of retinal ganglion cell death in glaucoma. Prog Retin Eye
|
|
Res, 2012, 31(2): 152-181. DOI: 10.1016/j.preteyeres.2011.11.
|
|
002.
|
|
002.
|
[11] |
Harada T, Harada C, Nakamura K, et al. The potential role of
|
[11] |
Harada T, Harada C, Nakamura K, et al. The potential role of
|
|
glutamate transporters in the pathogenesis of normal tension
|
|
glaucoma. J Clin Invest, 2007, 117(7): 1763-1770. DOI:
|
|
glutamate transporters in the pathogenesis of normal tension
|
|
glaucoma. J Clin Invest, 2007, 117(7): 1763-1770. DOI:
|
10 |
1172/JCI30178.
|
10 |
1172/JCI30178.
|
[12] |
Seki M, Soussou W, Manabe S, et al. Protection of retinal
|
[12] |
Seki M, Soussou W, Manabe S, et al. Protection of retinal
|
|
ganglion cells by caspase substrate-binding peptide IQACRG
|
|
ganglion cells by caspase substrate-binding peptide IQACRG
|
|
from N-methyl-D-aspartate receptor-mediated excitotoxicity.
|
|
Invest Ophthalmol Vis Sci, 2010, 51(2): 1198-1207. DOI:
|
|
from N-methyl-D-aspartate receptor-mediated excitotoxicity.
|
|
Invest Ophthalmol Vis Sci, 2010, 51(2): 1198-1207. DOI:
|
10 |
1167/iovs.09-4102.
|
10 |
1167/iovs.09-4102.
|
[13] |
Zeng K, Zhong B, Shen XL, et al. RNAi targeting Nogo
|
[13] |
Zeng K, Zhong B, Shen XL, et al. RNAi targeting Nogo
|
|
Receptor enhanced survival and proliferation of murine retinal
|
|
Receptor enhanced survival and proliferation of murine retinal
|
|
ganglion cells during N-methyl-D-aspartate-induced optic nerve
|
|
crush. Oncotarget, 2017, 8(39): 65009-65021. DOI: 10.18632/
|
|
ganglion cells during N-methyl-D-aspartate-induced optic nerve
|
|
crush. Oncotarget, 2017, 8(39): 65009-65021. DOI: 10.18632/
|
|
oncotarget.17351.
|
|
oncotarget.17351.
|
[14] |
Zhao J, Mysona BA, Qureshi A, et al. (+)-Pentazocine reduces
|
[14] |
Zhao J, Mysona BA, Qureshi A, et al. (+)-Pentazocine reduces
|
|
NMDA-induced murine retinal ganglion cell death through a
|
|
NMDA-induced murine retinal ganglion cell death through a
|
|
σR1-dependent mechanism. Invest Ophthalmol Vis Sci, 2016,
|
57 |
(2): 453-461. DOI: 10.1167/iovs.15-18565.
|
|
σR1-dependent mechanism. Invest Ophthalmol Vis Sci, 2016,
|
57 |
(2): 453-461. DOI: 10.1167/iovs.15-18565.
|
[15] |
Namekata K, Kimura A, Kawamura K, et al. Dock3 attenuates
|
[15] |
Namekata K, Kimura A, Kawamura K, et al. Dock3 attenuates
|
|
neural cell deathdue to NMDA neurotoxicity and oxidative
|
|
neural cell deathdue to NMDA neurotoxicity and oxidative
|
|
stress in a mouse model of normal tensionglaucoma. Cell Death
|
|
Differ, 2013, 20 (9): 1250-1256. DOI: 10.1038/cdd.2013.91.
|
|
stress in a mouse model of normal tensionglaucoma. Cell Death
|
|
Differ, 2013, 20 (9): 1250-1256. DOI: 10.1038/cdd.2013.91.
|
[16] |
Kimura A, Guo X, Noro T, et al. Valproic acid prevents
|
[16] |
Kimura A, Guo X, Noro T, et al. Valproic acid prevents
|
|
retinal degeneration in amurine model of normal tension
|
|
glaucoma. Neurosci Lett, 2015, 588: 108-113. DOI: 10.1016/
|
|
retinal degeneration in amurine model of normal tension
|
|
glaucoma. Neurosci Lett, 2015, 588: 108-113. DOI: 10.1016/
|
|
j.neulet.2014.12.054.
|
|
j.neulet.2014.12.054.
|
[17] |
Panossian A, Wikman G, Sarris J. Rosenroot (Rhodiolarosea):
|
[17] |
Panossian A, Wikman G, Sarris J. Rosenroot (Rhodiolarosea):
|
|
Traditionaluse, chemicalcomposition, pharmacologyand clinical
|
|
efficacy. Phytomedicine, 2010, 17(7): 481-493. DOI: 10.1016/
|
|
Traditionaluse, chemicalcomposition, pharmacologyand clinical
|
|
efficacy. Phytomedicine, 2010, 17(7): 481-493. DOI: 10.1016/
|
|
j.phymed.2010.02.002.
|
|
j.phymed.2010.02.002.
|
[18] |
Chen X, Liu J, Gu X, et a1. Salidroside attenuates glutamaateinduced
|
[18] |
Chen X, Liu J, Gu X, et a1. Salidroside attenuates glutamaateinduced
|
|
apoptotic cell death in primary cultured hippocamal
|
|
neurons of rats. Brain Res, 2008, 1238: 189-198.
|
|
apoptotic cell death in primary cultured hippocamal
|
|
neurons of rats. Brain Res, 2008, 1238: 189-198.
|
[19] |
Cao LL, Du GH, Wang MW. The effect of salidroside on cell
|
[19] |
Cao LL, Du GH, Wang MW. The effect of salidroside on cell
|
|
damage induced by glutamate and intracellular free calcium in
|
|
PC12 cells. J Asian Nat Prod Res, 2006, 8(1-2): 159-165. DOI:
|
10 |
1080/1028602042000325645.
|
|
damage induced by glutamate and intracellular free calcium in
|
|
PC12 cells. J Asian Nat Prod Res, 2006, 8(1-2): 159-165. DOI:
|
10 |
1080/1028602042000325645.
|
[20] |
Kim KO, Lee KH, Kim YH, et al. Anti-apoptotic role of
|
|
phospholipase D isozymes in the glutamate-induced cell death.
|
|
Exp Mol Med, 2003, 35(1): 38-45. DOI: 10.1038/emm.2003.6.
|
[20] |
Kim KO, Lee KH, Kim YH, et al. Anti-apoptotic role of
|
[21] |
Zhang W, He H, Song H, et al. Neuroprotective effects of
|
|
phospholipase D isozymes in the glutamate-induced cell death.
|
|
Exp Mol Med, 2003, 35(1): 38-45. DOI: 10.1038/emm.2003.6.
|
|
Salidroside in the MPTP mouse model of Parkinson's disease:
|
[21] |
Zhang W, He H, Song H, et al. Neuroprotective effects of
|
|
Involvement of the PI3K/Akt/GSK3β pathway. Parkinsons Dis,
|
|
Salidroside in the MPTP mouse model of Parkinson's disease:
|
20 |
16, 2016: 9450137. DOI: 10.1155/2016/9450137.
|
|
Involvement of the PI3K/Akt/GSK3β pathway. Parkinsons Dis,
|
20 |
16, 2016: 9450137. DOI: 10.1155/2016/9450137.
|
[22] |
张伟, 赵俊杰, 李涛, 等. 红景天苷对神经退行性疾病作用
|
|
的研究进展. 湖南中医药大学学报, 2016, 36(7): 86-90. DOI:
|
[22] |
张伟, 赵俊杰, 李涛, 等. 红景天苷对神经退行性疾病作用
|
10 |
3969/j.issn.1674-070X.2016.07.023.
|
|
的研究进展. 湖南中医药大学学报, 2016, 36(7): 86-90. DOI:
|
10 |
3969/j.issn.1674-070X.2016.07.023.
|
[23] |
张明发, 沈雅琴. 红景天苷的神经保护作用及作用机制研究
|
|
进展. 药物评价研究, 2017, 40(7): 1019-1028. DOI: 10.7501/
|
[23] |
张明发, 沈雅琴. 红景天苷的神经保护作用及作用机制研究
|
|
进展. 药物评价研究, 2017, 40(7): 1019-1028. DOI: 10.7501/
|
|
j.issn.1674-6376.2017.07.028.
|
|
j.issn.1674-6376.2017.07.028.
|
[24] |
Burugula B, Ganesh BS, Chintala SK. Curcumin attenuates
|
|
staurosporine-mediated death of retinal ganglion cells. Invest
|
[24] |
Burugula B, Ganesh BS, Chintala SK. Curcumin attenuates
|
|
Ophthalmol Vis Sci, 2011, 52(7): 4263-4273. DOI: 10.1167/
|
|
staurosporine-mediated death of retinal ganglion cells. Invest
|
|
Ophthalmol Vis Sci, 2011, 52(7): 4263-4273. DOI: 10.1167/
|
|
iovs.10-7103.
|
|
iovs.10-7103.
|